Navigation Links
Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

ested to study Abbott's Bcl-2 family protein inhibitors, which is an indication of the potential value that ABT-263 might bring to the cancer research field," said John Leonard, M.D., senior vice president, Pharmaceuticals, Research and Development, Abbott. "We have built an early stage pipeline that targets the processes that cancers need to survive and we're looking forward to advancing our work in this area."

Presentation highlights include:

-- A Phase I Study Evaluating the Safety, Pharmacokinetics, and Efficacy

of ABT-263 in Subjects With Refractory or Relapsed Lymphoid

Malignancies

-- Reduction in Platelet Counts as a Mechanistic Biomarker and Guide for

Adaptive Dose-escalation in Phase I Studies of the Bcl-2 Family

Inhibitor ABT-263

-- Dynamic Contrast Enhanced MRI (DCE MRI) for Assessment of Effects of

Anti-Angiogenic Therapy: Comparison of the Transfer Constant (Ktrans)

to Blood Flow and Permeability Derived by a Distributed Parameter

Model

-- Relationship of Dose of ABT-869 on Biomarkers of Angiogenesis and

Their Correlation With Pharmacodynamic (PD) Outcome

Study Background and Results

ABT-263

Thirty patients with refractory or relapsed lymphoid malignancies have been enrolled in an ongoing Phase I study evaluating safety, pharmacokinetics and efficacy. Subjects received ABT-263 orally once daily for 14 consecutive days followed by seven days off drug in each cycle of therapy. Results showed that ABT-263 had an acceptable side-effect profile at the seven-dose (10, 20, 40, 80, 160, 225 and 315 mg) cohort levels and showed evidence of anti-tumor activity. Researchers observed 99 percent and 36 percent tumor reduction in two patients with bulky chronic lymphocytic leukemia (CLL). Another patient with bulky CLL/small lymphocytic lymphoma (SLL) experienced a 75 percent reduction and a patient with follicular lymphom
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Abbott to Present at Citi Investment Research Global Health Care Conference
2. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
4. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
5. Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
6. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
7. Abbott Hosts Conference Call for First-Quarter Earnings
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
10. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
11. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... ... A July 9 article from USA Today has revealed a ... American Dental Association. According to a study by the American Dental Association, from 2000 ... single year to 2.2 million a year. Dentists and ADA officials all point to ...
(Date:8/3/2015)... ... ... Dignity Health named Dr. Norris A. Baldwin, Jr. the Facility Medical Director of ... The new facility is licensed under Dignity Health Arizona General Hospital , ... an excellent leader and will ensure our new freestanding emergency room delivers the highest ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Foot ... of a new associate podiatrist, creating the largest medical practice in the Mid-Atlantic region ... ankle medicine. FASMA operates 21 locations with 33 doctors. , Dr. Hetal Kathrotiya-Mago is ...
(Date:8/3/2015)... Louisville, KY (PRWEB) , ... August 03, 2015 , ... ... suffer from lower back pain at least once in their lives. Often time, low ... bulges. Until recently, disc herniations could only be managed clinically with powerful pain medication ...
(Date:8/2/2015)... ... August 02, 2015 , ... ... and connective tissues of a woman’s pelvic organs (uterus, bladder, and bowel) ... heavy lifting, obesity, constipation, multiple vaginal deliveries, genetics, smoking, and the aging ...
Breaking Medicine News(10 mins):Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4Health News:Dynamic Health Care in Louisville, KY, Offers a New and Cutting-Edge Therapy for Low Back & Leg Pain Sufferers 2Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2
... a statement released by Ranbaxy Pharmaceuticals Inc (RPI), they ... Award // from Wal-Mart, the largest chain store in ... of 2005. Wal-Mart Stores is a global company with ... stores and wholesale clubs across 10 countries. , ...
... cells that are responsible for causing epileptic seizures // ... of Medicine have identified glutamate receptor cells in the ... of glutamate when there is brain action that’s associated ... that will affect the protective glutamate receptors in increasing ...
... University of Michigan, who had long earlier published their findings ... ADHD, have come up with the results from the next ... the two. ,The follow up data of the ... who had snored regularly through their childhood are four times ...
... Cancer Institute and collaborating institutions have found sections of ... genes may lurk. , ,In a study ... Research, the researchers used single nucleotide polymorphism (SNP) array ... genes, to identify regions of chromosomes where genes were ...
... Vaccines for prophylaxis are well known. Famous vaccines include ... etc.; Therapeutic vaccines to cure a condition are more ... include the ones against HIV and hepatitis. The therapeutic ... combat an infectious agent, such as a virus. Now ...
... Statins are known to successfully treat atherosclerosis, the narrowing ... whether the drugs could also treat a similar condition ... valve in the heart. , ,According to a ... high doses of cholesterol-lowering drugs actually fail to treat ...
Cached Medicine News:Health News:Possible location of lung cancer genes found 2Health News:Understanding Chronic Infections May Help in Developing Therapeutic Vaccines 2
(Date:8/3/2015)... 3, 2015  EnteroMedics Inc. (NASDAQ: ETRM ), the ... obesity, metabolic diseases and other gastrointestinal disorders, today announced ... to the Board of Directors, effective July 31, 2015.  ... until the 2018 annual meeting or until her successor ... served in an executive capacity in the healthcare industry ...
(Date:8/2/2015)... , August 3, 2015 ... Dechra Pharmaceuticals PLC ("Dechra" or the "Company") is ... purchase agreement ("SPA") with Mr. Marijan Han žeković ... rights) in Genera d.d. ("Genera"), a Croatian listed pharmaceutical ... per share, which is equivalent to €51.4 million for ...
(Date:7/31/2015)... , July 31, 2015  Seeger Weiss LLP is ... (FDA) issued a warning letter to C.R. Bard, the manufacturer ... taking adequate strides to correct violations the agency found at ... these violations after the FDA cited them during Inspectional Observations ... in Bard,s Tempe, AZ , location and ...
Breaking Medicine Technology:EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... International Corporation (NASDAQ: PRXL ) announced today ... Conference in Boston, MA.  Josef von Rickenbach, Chairman and ... PAREXEL at 3:30 p.m. ET on Monday, March 5, 2012. ... presenting at the Raymond James Investors Conference in Orlando, ...
... ReportsnReports adds new market research report , ... and Market Forecasts to 2018 , to its ... $1,412.8m by 2018 growing at a CAGR of 5%. The ... for minimally invasive procedures and technology advances that make surgery ...
Cached Medicine Technology:PAREXEL International to Present at Cowen Healthcare Conference and Raymond James Investors Conference 2Electrosurgical Devices Market to Grow at a CAGR of 5% Globally From 2011-2018 2Electrosurgical Devices Market to Grow at a CAGR of 5% Globally From 2011-2018 3Electrosurgical Devices Market to Grow at a CAGR of 5% Globally From 2011-2018 4
... new 4351 Intramuscular Lead is a unipolar lead ... 4351 lead has a ski needle design for ... designed with a fixed electrode length of 1 ... neurostimulator and is available in 35 cm length. ...
... AwareTM HIV-1/2 OMT test is a single ... for the,detection of antibodies to Human Immunodeficiency ... (HIV-2) in human oral,mucosal transudate specimens. It ... aid in the clinical diagnosis of HIV,infection. ...
... control available with intact red blood cells ... the lysing of the red blood cell. ... with an open-vial stability of 30 days ... when refrigerated. A1c-Cellular is appropriate for immunoassay ...
...
Medicine Products: